Skip to content
MS
Sign in
unreviewed

Fumarase (fumarate hydratase)

1 reactions · 1 pathways

Cofactors used

H2O

Clinical / pharmacological. FH mutations: hereditary leiomyomatosis and renal cell carcinoma

What it does, reaction by reaction

1 reactions

Citric Acid Cycle (TCA / Krebs Cycle) Energy Metabolism & Cellular Respiration · Mitochondrial matrix

step 7 Reversible

Fumarate + H2O ⇌ L-malate

Converts Fumarate H2O into Malate

› Notes

Required cofactor: none beyond water. The reaction is reversible and forms only L-malate.

Showing all 1 reactions.

What accelerates and inhibits it

Regulation is pathway-specific, so each context is listed separately

0 entries

No regulation recorded for this enzyme in the source documents.

Recent literature

Refresh

Europe PMC · fetched just now · sorted by publication date

  1. 1
    Global, regional, and national burden of exposure to chewing tobacco, 1990-2023: a systematic analysis of the Global Burden of Disease Study 2023.

    GBD 2023 Chewing Tobacco Collaborators. · 2027-07-20

    unreviewed
  2. 2
    Multi-omics studies identified the molecular network of mitochondrial dysfunction in the pathogenesis of breast cancer.

    Liu J, Guan X, Quan L, Dou M, Yuan P. · 2026-05-17

    open access unreviewed
  3. 3
    Transient culture of adult human hepatocytes as organoids improves engineered liver engraftment.

    Saxton SH, Kang I, Mitchell S, Lotto J, Upadhyay A, Zou C, Quirk C, McCray TN, Prado O, Johansson F, Fortin C… · 2026-07-23

    open access unreviewed
  4. 4
    MergeRepair: An Exploratory Study on Merging Task-Specific Adapters in Code LLMs for Automated Program Repair.

    Dehghan M, Wu JJ, Fard FH, Ouni A. · 2026-09-25

    open access unreviewed
  5. 5
    Polyoxometalate-derived WSSe nanoparticles confined in carbon nanofibers for fast and durable lithium storage.

    Ren FH, Chen JP, Zhao XJ, Wen Z, Zheng ST, Cai PW. · 2026-08-11

    unreviewed
  6. 6
    Willingness to contribute monetarily for hereditary breast cancer risk testing and the influencing factors: The first Indonesian exploration in the province with the highest prevalence.

    Putri ARA, Hermansyah A, Kristina SA, Trung VQ, Alfian SD, Ming LC. · 2026-09-21

    open access unreviewed
  7. 7
    Implementation of an EHR-supported multidisciplinary lipid management program for suspected familial hypercholesterolemia: Early clinical and implementation outcomes.

    Fishberg RD, Feldman JN, Dubose D, Cooper L, Rutledge J. · 2026-07-11

    open access unreviewed
  8. 8
    Treatment patterns in homozygous familial hypercholesterolemia: Undertreatment and delayed adoption of low-density lipoprotein receptor-independent therapies.

    Murdock DJ, Wang L, Gu J, Sanchez RJ, Godin R, Brandt EJ. · 2026-08-05

    open access unreviewed
  9. 9
    Clinical considerations on the use of evinacumab for the treatment of homozygous familial hypercholesterolemia.

    Bajaj A, McGuire M, Shugg S, Godin R, Underberg JA. · 2026-08-11

    open access unreviewed
  10. 10
    Systematic review of clinical guidance for lipid management in adults with or at risk of atherosclerotic cardiovascular disease: A global perspective.

    Akers KG, Nguyen K, Frederickson AM, Bash LD, Ke X, Goodman SG. · 2026-09-17

    open access unreviewed

External claims. These come from an index outside this database and are not checked against it. Treat them as leads.